BLOCKade of Calcium Channels and Beta Adrenergic Receptors for the Treatment of Hypertension in HFpEF
Status:
Recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
Heart failure with preserved ejection fraction (HFpEF) is a critical public health problem.
Heart failure (HF) affects over 5 million adults in the United States (US), and is a major
source of morbidity, mortality, and impaired quality of life. Approximately half of
individuals with HF have a preserved left ventricular (LV) ejection fraction (EF), termed HF
with preserved EF (HFpEF). While there are several effective pharmacologic therapies for HF
with reduced ejection fraction (HFrEF), none have been identified for HFpEF. Hypertension,
which is present in approximately 80% of individuals with HFpEF, is the foremost modifiable
risk factor for the development and progression of HFpEF. Despite the clinical importance of
hypertension in HFpEF, there is limited information on how common antihypertensive agents,
particularly calcium channel blockers (CCBs) and β-blockers, effect pathophysiologic
mechanisms of HFpEF. This is a mechanistic investigation of the role of dihydropyridine CCBs
compared to β-blockers (commonly used antihypertensive agents in clinical practice) in
targeting key physiologic abnormalities in HFpEF.